


ContraFect

COMPANY OVERVIEW

ContraFect is a clinical stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. An estimated 700,000 deaths worldwide each year are attributed to antimicrobial-resistant infections. Our lysin and monoclonal antibody platforms target conserved regions of bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (methicillin resistant *Staph aureus*) and influenza.



STOCK OVERVIEW

Symbol	CFRX
Exchange	Nasdaq
Market Cap	43.52m
Last Price	\$0.548
52-Week Range	\$0.5481 - \$2.9266

01/18/2019 04:00 PM EST

INVESTOR RELATIONS

Michael Messinger
T: 914-207-2300
mmessinger@contrafect.com

CONTRAFECT CORPORATION

28 Wells Avenue
3rd Floor
Yonkers, NY 10701
US

RECENT NEWS

ContraFect Announces Additional \$2.3 Million in Funding from CARB-X to Support Gram-Negative Lysin Program

Jan 17 2019, 7:00 AM EST

ContraFect's Exebacase (CF-301) Improved Clinical Outcomes in *Staphylococcus aureus* Bacteremia including Right-Sided Endocarditis Compared to Standard of Care Antibiotics Alone in a First-in-Patient Phase 2 Superiority Study

Jan 7 2019, 7:00 AM EST

ContraFect to Present at Biotech Showcase 2019

Dec 20 2018, 5:00 PM EST

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.